Skip to main content
Erschienen in: International Urology and Nephrology 7/2019

22.04.2019 | Nephrology - Original Paper

Correlation of serum galectin-3 level with renal volume and function in adult polycystic kidney disease

verfasst von: Sultan Ozkurt, Ibrahim Dogan, Oguzhan Ozcan, Nurdan Fidan, Ilter Bozaci, Behice Yilmaz, Muzaffer Bilgin

Erschienen in: International Urology and Nephrology | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The decrease in kidney functions in autosomal dominant polycystic kidney disease (ADPKD) is strongly correlated with the severity and growth of kidney cysts. Total kidney volume (TKV) was shown to be an early marker of the severity of the disease and a predictor of reduction in kidney functions. New treatment approaches for ADPKD have led to a need for easily applicable strong biomarkers predicting progression of the disease. The profibrotic mediator of galectin-3 (Gal-3) is linked to development of renal fibrosis.

Methods

The study included 74 patients with ADPKD diagnosis and 40 healthy controls. The TKV of patients was calculated using the manual tracing method on MR images. The serum Gal-3 levels of patient and healthy control groups were measured with the ELISA method. The correlations between serum Gal-3 value with TKV and kidney function were assessed in patients.

Results

As the stage of chronic kidney disease (CKD) increased, serum Gal-3 and TKV values increased (p < 0.001, p = 0.049, respectively). Correlation analysis found a negative relationship between serum Gal-3 levels and eGFR (r: − 0.515, p < 0.001); however, there was no relationship between serum Gal-3 and TKV (r = 0.112, p = 0.344). Linear regression analysis showed the major parameter affecting Gal-3 was eGFR (p = 0.016).

Conclusions

In our study, we showed that renal impairment is an important determinant of Gal-3, and there is no correlation of Gal-3 and TKV in ADPKD. As a result, there is an urgent clinical need for new biomarkers to identify individuals with the chance of treatment in the early stage among ADPKD patients.
Literatur
1.
Zurück zum Zitat Spithoven EM, Kramer A, Meijer E et al (2014) Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival—an analysis of data from the ERA-EDTA registry. Nephrol Dial Transplant 29:15–25CrossRef Spithoven EM, Kramer A, Meijer E et al (2014) Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival—an analysis of data from the ERA-EDTA registry. Nephrol Dial Transplant 29:15–25CrossRef
2.
Zurück zum Zitat Grantham JJ, Chapman AB, Torres VE (2006) Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol 1:148–157CrossRefPubMed Grantham JJ, Chapman AB, Torres VE (2006) Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol 1:148–157CrossRefPubMed
3.
4.
Zurück zum Zitat Grantham JJ, Torres VE, Chapman AB et al (2006) Volume progression in polycystic kidney disease. N Engl J Med 354:2122–2130CrossRefPubMed Grantham JJ, Torres VE, Chapman AB et al (2006) Volume progression in polycystic kidney disease. N Engl J Med 354:2122–2130CrossRefPubMed
5.
Zurück zum Zitat Chapman AB, Devuyst O, Eckardt KU et al (2015) Autosomal—dominant polycystic kidney disease (ADPKD): executive summary from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 88:17–27CrossRefPubMedPubMedCentral Chapman AB, Devuyst O, Eckardt KU et al (2015) Autosomal—dominant polycystic kidney disease (ADPKD): executive summary from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 88:17–27CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Torres VE, Chapman AB, Devuyst O et al (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367:2407–2418CrossRefPubMedPubMedCentral Torres VE, Chapman AB, Devuyst O et al (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367:2407–2418CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Magistroni R, Corsi C, Martí T, Torra R (2018) A review of the imaging techniques for measuring kidney and cyst volume in establishing autosomal dominant polycystic kidney disease progression. Am J Nephrol 48:67–78CrossRefPubMed Magistroni R, Corsi C, Martí T, Torra R (2018) A review of the imaging techniques for measuring kidney and cyst volume in establishing autosomal dominant polycystic kidney disease progression. Am J Nephrol 48:67–78CrossRefPubMed
8.
Zurück zum Zitat Chapman AB, Guay-Woodford LM, Grantham JJ et al (2003) Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the consortium for radiologic imaging studies of polycystic kidney disease (CRISP) cohort. Kidney Int 64:1035–1045CrossRefPubMed Chapman AB, Guay-Woodford LM, Grantham JJ et al (2003) Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the consortium for radiologic imaging studies of polycystic kidney disease (CRISP) cohort. Kidney Int 64:1035–1045CrossRefPubMed
9.
Zurück zum Zitat Grantham JJ (2015) Rationale for early treatment of polycystic kidney disease. Pediatr Nephrol 30:1053–1062CrossRefPubMed Grantham JJ (2015) Rationale for early treatment of polycystic kidney disease. Pediatr Nephrol 30:1053–1062CrossRefPubMed
10.
Zurück zum Zitat Grantham JJ, Mulamalla S, Swenson-Fields KI (2011) Why kidneys fail in autosomal dominant polycystic kidney disease. Nat Rev Nephrol 7:556–566CrossRefPubMed Grantham JJ, Mulamalla S, Swenson-Fields KI (2011) Why kidneys fail in autosomal dominant polycystic kidney disease. Nat Rev Nephrol 7:556–566CrossRefPubMed
11.
Zurück zum Zitat Dhirapong A, Lleo A, Leung P, Gershwin ME, Liu FT (2009) The immunological potential of galectin-1 and -3. Autoimmun Rev 8:360–363CrossRefPubMed Dhirapong A, Lleo A, Leung P, Gershwin ME, Liu FT (2009) The immunological potential of galectin-1 and -3. Autoimmun Rev 8:360–363CrossRefPubMed
12.
Zurück zum Zitat Henderson NC, Sethi T (2009) The regulation of inflammation by galectin-3. Immunol Rev 203:160–171CrossRef Henderson NC, Sethi T (2009) The regulation of inflammation by galectin-3. Immunol Rev 203:160–171CrossRef
14.
Zurück zum Zitat Sharma UC, Pokharel S, van Brakel TJ et al (2004) Galectin-3 marks activated macrophages in failure prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110:3121–3128CrossRefPubMed Sharma UC, Pokharel S, van Brakel TJ et al (2004) Galectin-3 marks activated macrophages in failure prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110:3121–3128CrossRefPubMed
15.
Zurück zum Zitat de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ (2009) Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 11:811–817CrossRefPubMed de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ (2009) Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 11:811–817CrossRefPubMed
16.
Zurück zum Zitat Lok DJ, Van Der Meer P, de la Porte PW et al (2010) Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure. Clin Res Cardiol 99:323–328CrossRefPubMedPubMedCentral Lok DJ, Van Der Meer P, de la Porte PW et al (2010) Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure. Clin Res Cardiol 99:323–328CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Lin YH, Lin LY, Wu YW et al (2009) The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 409:96–99CrossRefPubMed Lin YH, Lin LY, Wu YW et al (2009) The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 409:96–99CrossRefPubMed
18.
Zurück zum Zitat McCullough PA, Olobatoke A, Vanhecke TE (2011) Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med 12:200–210PubMed McCullough PA, Olobatoke A, Vanhecke TE (2011) Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med 12:200–210PubMed
19.
Zurück zum Zitat Grupper A, Nativi-Nicolau J, Maleszewski JJ et al (2016) Circulating galectin-3 levels are persistently elevated after heart transplantation and are associated with renal dysfunction. JACC Heart Fail 4:847–856CrossRefPubMed Grupper A, Nativi-Nicolau J, Maleszewski JJ et al (2016) Circulating galectin-3 levels are persistently elevated after heart transplantation and are associated with renal dysfunction. JACC Heart Fail 4:847–856CrossRefPubMed
20.
Zurück zum Zitat Meijers WC, van der Velde AR, Ruifrok WP et al (2014) Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis. J Am Heart Assoc 3:e000962CrossRefPubMedPubMedCentral Meijers WC, van der Velde AR, Ruifrok WP et al (2014) Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis. J Am Heart Assoc 3:e000962CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Gopal DM, Kommineni M, Ayalon N et al (2012) Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J Am Heart Assoc 1:e000760CrossRefPubMedPubMedCentral Gopal DM, Kommineni M, Ayalon N et al (2012) Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J Am Heart Assoc 1:e000760CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat O’Seaghdha CM, Hwang SJ, Ho JE, Vasan RS, Levy D, Fox CS (2013) Elevated galectin-3 precedes the development of CKD. J Am Soc Nephrol 24:1880–1888CrossRefPubMedPubMedCentral O’Seaghdha CM, Hwang SJ, Ho JE, Vasan RS, Levy D, Fox CS (2013) Elevated galectin-3 precedes the development of CKD. J Am Soc Nephrol 24:1880–1888CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Bullock SL, Johnson TM, Bao Q, Hughes RC, Winyard PJ, Woolf AS (2001) Galectin-3 modulates ureteric bud branching in organ culture of the developing mouse kidney. J Am Soc Nephrol 12:515–523PubMed Bullock SL, Johnson TM, Bao Q, Hughes RC, Winyard PJ, Woolf AS (2001) Galectin-3 modulates ureteric bud branching in organ culture of the developing mouse kidney. J Am Soc Nephrol 12:515–523PubMed
24.
Zurück zum Zitat Hikita C, Vijayakumar S, Takito J, Erdjument- Bromage H, Tempst P, Al-Awqati Q (2000) Induction of terminal differentiation in epithelial cells requires polymerization of hensin by galectin 3. J Cell Biol 151:1235–1246CrossRefPubMedPubMedCentral Hikita C, Vijayakumar S, Takito J, Erdjument- Bromage H, Tempst P, Al-Awqati Q (2000) Induction of terminal differentiation in epithelial cells requires polymerization of hensin by galectin 3. J Cell Biol 151:1235–1246CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Guay-Woodford LM, Desmond RA (2003) Autosomal recessive polycystic kidney disease: the clinical experience in North America. Pediatrics 111:1072–1080CrossRefPubMed Guay-Woodford LM, Desmond RA (2003) Autosomal recessive polycystic kidney disease: the clinical experience in North America. Pediatrics 111:1072–1080CrossRefPubMed
26.
Zurück zum Zitat Bao Q, Hughes RC (1999) Galectin-3 and polarized growth within collagen gels of wild-type and ricin-resistant MDCK renal epithelial cells. Glycobiology 9:489–495CrossRefPubMed Bao Q, Hughes RC (1999) Galectin-3 and polarized growth within collagen gels of wild-type and ricin-resistant MDCK renal epithelial cells. Glycobiology 9:489–495CrossRefPubMed
27.
Zurück zum Zitat Olsan EE, West JD, Torres JA, Doerr N, Weimbs T (2018) Identification of targets of IL-13 and STAT6 signaling in polycystic kidney disease. Am J Physiol Renal Physiol 1(315):86–96CrossRef Olsan EE, West JD, Torres JA, Doerr N, Weimbs T (2018) Identification of targets of IL-13 and STAT6 signaling in polycystic kidney disease. Am J Physiol Renal Physiol 1(315):86–96CrossRef
28.
Zurück zum Zitat Fernandes Bertocchi AP, Campanhole G, Wang PH et al (2018) A role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury. Transpl Int 21:999–1007CrossRef Fernandes Bertocchi AP, Campanhole G, Wang PH et al (2018) A role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury. Transpl Int 21:999–1007CrossRef
29.
30.
Zurück zum Zitat Vansthertem D, Cludts S, Nonclercq D et al (2010) Immunohistochemical localization of galectins-1 and -3 and monitoring of tissue galectin-binding sites during tubular regeneration after renal ischemia reperfusion in the rat. Histol Histopathol 25:1417–1429PubMed Vansthertem D, Cludts S, Nonclercq D et al (2010) Immunohistochemical localization of galectins-1 and -3 and monitoring of tissue galectin-binding sites during tubular regeneration after renal ischemia reperfusion in the rat. Histol Histopathol 25:1417–1429PubMed
31.
Zurück zum Zitat Okamura DM, Pasichnyk K, Lopez-Guisa JM et al (2010) Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis. Am J Physiol Renal Physiol 300:245–253CrossRef Okamura DM, Pasichnyk K, Lopez-Guisa JM et al (2010) Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis. Am J Physiol Renal Physiol 300:245–253CrossRef
32.
Zurück zum Zitat Kang EH, Moon KC, Lee EY et al (2009) Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis. Lupus 18:22–28CrossRefPubMed Kang EH, Moon KC, Lee EY et al (2009) Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis. Lupus 18:22–28CrossRefPubMed
33.
Zurück zum Zitat Mann DL (1999) Inflammatory mediators in heart failure: homogeneity through heterogeneity. Lancet 353:1812–1813CrossRefPubMed Mann DL (1999) Inflammatory mediators in heart failure: homogeneity through heterogeneity. Lancet 353:1812–1813CrossRefPubMed
34.
Zurück zum Zitat Dancer JY, Truong LD, Zhai Q, Shen SS (2010) Expression of galectin-3 in renal neoplasms: a diagnostic, possible prognostic marker. Arch Pathol Lab Med 134:90–94PubMed Dancer JY, Truong LD, Zhai Q, Shen SS (2010) Expression of galectin-3 in renal neoplasms: a diagnostic, possible prognostic marker. Arch Pathol Lab Med 134:90–94PubMed
Metadaten
Titel
Correlation of serum galectin-3 level with renal volume and function in adult polycystic kidney disease
verfasst von
Sultan Ozkurt
Ibrahim Dogan
Oguzhan Ozcan
Nurdan Fidan
Ilter Bozaci
Behice Yilmaz
Muzaffer Bilgin
Publikationsdatum
22.04.2019
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 7/2019
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-019-02156-8

Weitere Artikel der Ausgabe 7/2019

International Urology and Nephrology 7/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.